Phenytoin: From Historical Anticonvulsant to Modern Clinical Practice

For the clinician, the first seizure after a traumatic brain injury can be a race against time. In a 2022 nationwide study, 18% of patients with acute head trauma experienced an unprovoked seizure within 24 hours, and early anticonvulsant therapy reduced mortality by nearly 12%. Phenytoin, introduced in the 1940s, is still the drug of choice for many acute and chronic seizure disorders, making its pharmacology essential knowledge for every pharmacy and medical student.

Introduction and Background

Phenytoin (diphenylhydantoin) was first synthesized by Paul Ehrlich’s team in 1898 and entered clinical use in 1948. Its discovery marked the transition from crude plant extracts to rationally designed small molecules in neurology. The drug belongs to the hydantoin class of anticonvulsants, which also includes phenobarbital and carbamazepine. Epidemiologically, epilepsy affects roughly 1% of the global population, and approximately 70% of patients achieve seizure control with a single antiepileptic drug. Phenytoin remains a first‑line agent for generalized tonic‑clonic seizures, status epilepticus, and certain focal seizures, particularly in resource‑limited settings where cost and availability are critical considerations.

Phenytoin’s mechanism of action is multifaceted, involving voltage‑gated sodium channel inhibition, modulation of calcium channels, and indirect effects on GABAergic neurotransmission. Unlike newer agents that act selectively, phenytoin’s broad spectrum of action underlies both its therapeutic efficacy and its notorious side‑effect profile. Understanding the drug’s pharmacological nuances is vital for optimizing dosing, minimizing toxicity, and anticipating drug‑drug interactions.

Mechanism of Action

Voltage‑Gated Sodium Channel Inhibition

Phenytoin preferentially binds to the inactivated state of voltage‑gated sodium channels (Nav1.1–1.9) in neurons. By stabilizing the channel in this closed conformation, phenytoin reduces the amplitude and frequency of action potentials, thereby dampening hyperexcitability. This action is concentration‑dependent and exhibits a classic non‑linear pharmacodynamic curve, with therapeutic effects emerging only after plasma concentrations surpass 10 µg/mL.

Modulation of Calcium Channels

Beyond sodium channels, phenytoin also inhibits T‑type calcium channels (CaV3.1–3.3), which are implicated in thalamocortical oscillations that drive absence seizures. The dual blockade of sodium and calcium currents contributes to phenytoin’s broad seizure‑control spectrum.

Indirect Enhancement of GABAergic Transmission

Several studies demonstrate that phenytoin increases GABA release and potentiates GABA_A receptor activity, although the exact mechanism remains unclear. This indirect potentiation may explain its efficacy in refractory partial seizures and its synergistic effect when combined with benzodiazepines during status epilepticus.

Clinical Pharmacology

Phenytoin’s pharmacokinetics are notoriously nonlinear due to saturable metabolism by the cytochrome P450 2C9 and 2C19 isoenzymes. The drug’s bioavailability is highly variable (30–70%) and is reduced by food intake. Distribution is extensive; the protein binding is approximately 90%, predominantly to albumin. The elimination half‑life ranges from 7 to 20 hours, depending on dose and patient factors. Renal excretion accounts for less than 10% of the dose; hepatic metabolism is the primary route.

Therapeutic Applications

• Acute Recurrent Seizures: 4–5 mg/kg IV over 15–30 minutes, then maintenance 300–600 mg/day orally.
• Status Epilepticus: 20–30 mg/kg IV (maximum 1 g), followed by continuous infusion at 4–8 mg/kg/h.
• Generalized Tonic‑Clonic Seizures: 5–10 mg/kg/day orally, titrated to 300–600 mg/day.
• Partial Seizures: 5–10 mg/kg/day orally, titrated to 300–600 mg/day.
• Neonatal Status Epilepticus: 20–30 mg/kg IV, limited data on long‑term outcomes.
• Off‑Label Uses: Migraine prophylaxis (low‑dose 25–50 mg/day), trigeminal neuralgia, and certain movement disorders.

Special populations require dose adjustments:

1. Pediatrics (0–12 yrs): Weight‑based dosing; careful monitoring of serum trough levels due to rapid maturation of CYP enzymes.
2. Geriatrics: Reduced hepatic function may prolong half‑life; start at 1/3 of adult dose.
3. Renal Impairment: Minimal renal clearance; dose adjustment not routinely required but monitor for toxicity.
4. Hepatic Impairment: Significant reduction in clearance; start at 1/3 dose and titrate slowly.
5. Pregnancy: Fetal exposure leads to neural tube defects and cleft palate; use only if benefits outweigh risks; consider alternative agents.

Adverse Effects and Safety

Phenytoin’s side‑effect profile is dose‑dependent and includes both acute and chronic manifestations. Common adverse effects and their approximate incidence are:

• Acute: Nystagmus (10–15%), ataxia (5–10%), dizziness (5–10%).
• Chronic: Gingival hyperplasia (10–20%), hirsutism (5–10%), skin rash (1–2%).
• Serious: Steven–Johnson syndrome (0.1–0.2%), aplastic anemia (0.01–0.05%), drug‑induced liver injury (0.1–0.5%).
• Black Box Warning: Life‑threatening hypersensitivity reactions and teratogenicity.

Monitoring parameters include: serum phenytoin trough (target 10–20 µg/mL), liver function tests, complete blood count, and pregnancy screening in women of childbearing age.

Clinical Pearls for Practice

• Remember the “S‑curve”: Small dose increases near the therapeutic window produce large rises in serum concentration due to saturable metabolism.
• Use the “Phenytoin Trough” mnemonic: “Threshold Reaches Only Up Responses Higher On Re‑titration.”
• Start low, go slow: In geriatric patients, initiate at 1/3 of the adult dose and titrate over 2–4 weeks.
• Watch for “Nystagmus”: Persistent horizontal nystagmus after loading dose signals toxicity—hold the drug and re‑check levels.
• Pregnancy caution: If phenytoin therapy is unavoidable, counsel patients on folic acid supplementation and schedule early ultrasound.
• Drug‑drug synergy: Combining phenytoin with benzodiazepines during status epilepticus is synergistic; avoid simultaneous use of multiple sodium‑channel blockers.
• Renal clearance is minimal: Dose adjustments are rarely needed for renal impairment; focus on hepatic function.

Comparison Table

Exam‑Focused Review

Common exam question stems include:

• Which anticonvulsant is most likely to cause gingival hyperplasia and requires monitoring of serum trough levels?
• A 45‑year‑old patient on phenytoin develops a maculopapular rash; what is the next best step?
• Which drug interaction will most likely lower phenytoin serum levels in a patient also taking carbamazepine?
• What is the therapeutic range for phenytoin in mg/L?

Key differentiators:

• Phenytoin vs. carbamazepine: both inhibit sodium channels, but carbamazepine is more associated with hyponatremia and less gingival hyperplasia.
• Phenytoin vs. valproate: valproate is a broad‑spectrum agent with a higher risk of hepatotoxicity; phenytoin is more cost‑effective in low‑resource settings.
• Phenytoin vs. lacosamide: lacosamide selectively targets slow‑inactivation of sodium channels and is less likely to cause gingival hyperplasia.

Must‑know facts for NAPLEX, USMLE, and clinical rotations:

1. Phenytoin follows Michaelis‑Menten kinetics; small dose increases near the therapeutic window can precipitate toxicity.
2. The therapeutic range is 10–20 µg/mL; levels <10 µg/mL are subtherapeutic, >20 µg/mL increase the risk of adverse effects.
3. Phenytoin is teratogenic; it causes neural tube defects and cleft palate, especially in the first trimester.
4. Common drug interactions include induction by carbamazepine and inhibition by cimetidine.
5. Monitoring includes serum phenytoin trough, CBC, LFTs, and pregnancy screening.
6. In status epilepticus, phenytoin can be given IV or via continuous infusion; avoid bolus doses >30 mg/kg to prevent arrhythmias.
7. Gingival hyperplasia is dose‑related and reversible upon discontinuation.
8. Phenytoin’s half‑life is prolonged in hepatic impairment; start at 1/3 dose and titrate slowly.

Key Takeaways

1. Phenytoin is a versatile anticonvulsant with a complex, saturable metabolism.
2. Therapeutic serum levels are 10–20 µg/mL; monitoring is essential due to narrow therapeutic index.
3. Its mechanism centers on sodium channel inhibition, with ancillary effects on calcium channels and GABAergic transmission.
4. Common adverse effects include gingival hyperplasia, hirsutism, and nystagmus.
5. Phenytoin is teratogenic; avoid in pregnancy unless no alternatives exist.
6. Drug interactions can significantly alter serum concentrations; adjust dosing accordingly.
7. Special populations require careful dose titration and monitoring, especially the elderly and hepatic‑impaired patients.
8. In status epilepticus, phenytoin is effective but requires caution with bolus dosing to prevent cardiac arrhythmias.
9. Phenytoin’s cost and availability make it a valuable first‑line agent in low‑resource settings.
10. Regular monitoring of serum levels, CBC, LFTs, and pregnancy status is mandatory for safe therapy.

Always remember: phenytoin’s narrow therapeutic window and complex metabolism demand vigilant monitoring and patient education to ensure safe and effective seizure control.